Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations.
Glyburide was granted FDA approval on 1 May 1984. A formulation with metformin was granted FDA approval on on 31 July 2000.
Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
St Johns Hospital, Livingston, West Lothian, United Kingdom
Princess Royal Infirmary, Glasgow, Lanarkshire, United Kingdom
Western General Hospital, Edinburgh, Lothian, United Kingdom
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
Azienda Opedaliera-Universitaria, Parma, Italy
Azienda Ospedaliera-Universitaria, Parma, Italy
University of Maryland School of Medicine, Baltimore, Maryland, United States
UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States
Cleveland Clinic, Cleveland, Ohio, United States
Marie-Victoire Senat, Paris, France
Washington University in St. Louis Clinical Research Unit (CRU), St. Louis, Missouri, United States
Novo Nordisk Investigational Site, Padova, Italy
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.